Ardelyx, Inc. (ARDX)Healthcare | Biotechnology | Waltham, United States | NasdaqGM
3.81 USD
-0.01
(-0.262%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 3.84 +0.03 (0.745%) ⇧ (Aug. 28, 2026, 7:43 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 5:40 a.m. EDT
The investment case for Ardelyx is currently paralyzed by a stark disconnect between its operational recovery and its capital structure. Fundamentally, the company is turning the corner: revenue is growing at 23.8%, gross margins are healthy at 75%, and the stock has finished the trailing decade with a net gain, avoiding the dreaded multi-year decline penalty. The balance sheet is fortified with a 3.3 current ratio and nearly $282 million in cash, providing ample runway for R&D and commercialization. However, the short-term outlook is clouded by a precarious debt situation. With total debt matching cash reserves at roughly $282 million, the company is effectively net-cash-neutral, leaving no safety margin for unexpected burn or market stress. This fragility explains the crushing 8.7 short ratio and the aggressive bearish positioning seen in the options chain, where traders are stacking heavy put protection. While analysts see a path to profitability and a potential 3x upside to their mean target, the market is pricing in a 'value trap' scenario due to the debt overhang and historical volatility. Until the balance sheet is strengthened or the path to sustained profitability is proven beyond doubt, the risk-reward profile remains skewed against the buyer. The stock is a speculative turnaround play, not a core holding. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.064317 |
| AutoETS | 0.064317 |
| AutoTheta | 0.064371 |
| MSTL | 0.066174 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 31% |
| H-stat | 1.67 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.006 |
| Excess Kurtosis | 2.23 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 189.585 |
| Revenue per Share | 1.841 |
| Market Cap | 983,694,592 |
| Forward P/E | 15.12 |
| Beta | 0.73 |
| Profit Margins | -12.35% |
| Website | https://www.ardelyx.com |
As of Aug. 22, 2026, 5:40 a.m. EDT: Speculators are heavily positioned for downside protection, with massive open interest in out-of-the-money puts (strikes 5.0 and 10.0) compared to negligible call volume. The call side shows a distinct 'long gamma' setup where traders are buying deep out-of-the-money calls (strikes 6.0 and 7.0) while selling or holding very few in-the-money calls, suggesting a bet on a volatile gap up rather than steady appreciation. However, the overwhelming put volume indicates the market expects significant volatility or a drop below current levels.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.403125 |
| Address1 | 400 Fifth Avenue |
| Address2 | Suite 210 |
| All Time High | 35.48 |
| All Time Low | 0.49 |
| Ask | 6.45 |
| Ask Size | 2 |
| Audit Risk | 8 |
| Average Analyst Rating | 1.1 - Strong Buy |
| Average Daily Volume10 Day | 3,602,110 |
| Average Daily Volume3 Month | 4,210,151 |
| Average Volume | 4,210,151 |
| Average Volume10Days | 3,602,110 |
| Beta | 0.731 |
| Bid | 3.62 |
| Bid Size | 2 |
| Board Risk | 6 |
| Book Value | 0.598 |
| City | Waltham |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 7 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 3.81 |
| Current Ratio | 3.342 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 3.8995 |
| Day Low | 3.75 |
| Debt To Equity | 189.585 |
| Display Name | Ardelyx |
| Earnings Call Timestamp End | 1,786,048,200 |
| Earnings Call Timestamp Start | 1,786,048,200 |
| Earnings Timestamp | 1,786,046,400 |
| Earnings Timestamp End | 1,793,304,000 |
| Earnings Timestamp Start | 1,793,304,000 |
| Ebitda | -32,106,000 |
| Ebitda Margins | -0.07121 |
| Enterprise To Ebitda | -29.592 |
| Enterprise To Revenue | 2.107 |
| Enterprise Value | 950,081,664 |
| Eps Current Year | -0.20092 |
| Eps Forward | 0.25198 |
| Eps Trailing Twelve Months | -0.23 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 4.8982 |
| Fifty Day Average Change | -1.0882001 |
| Fifty Day Average Change Percent | -0.22216326 |
| Fifty Two Week Change Percent | -40.3125 |
| Fifty Two Week High | 8.4 |
| Fifty Two Week High Change | -4.5899997 |
| Fifty Two Week High Change Percent | -0.54642856 |
| Fifty Two Week Low | 3.725 |
| Fifty Two Week Low Change | 0.08500004 |
| Fifty Two Week Low Change Percent | 0.022818802 |
| Fifty Two Week Range | 3.725 - 8.4 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,403,184,600,000 |
| Float Shares | 210,663,173 |
| Forward Eps | 0.25198 |
| Forward P E | 15.120247 |
| Free Cashflow | 20,468,000 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 489 |
| Fullday Change | -0.00999999 |
| Fullday Change Percent | -0.26178 |
| Fullday Price | 3.8384 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.75024 |
| Gross Profits | 338,279,008 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0317 |
| Held Percent Institutions | 0.73307997 |
| Implied Shares Outstanding | 258,187,572 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx, Inc. was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. The company was incorporated in 2007 and is headquartered in Waltham, Massachusetts. |
| Long Name | Ardelyx, Inc. |
| Market | us_market |
| Market Cap | 983,694,592 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_58915635 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -55,702,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 983,694,649 |
| Number Of Analyst Opinions | 10 |
| Open | 3.81 |
| Operating Cashflow | -17,320,000 |
| Operating Margins | -0.102790006 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 510 745 1700 |
| Post Market Change | 0.028399944 |
| Post Market Change Percent | 0.7454054 |
| Post Market Price | 3.8384 |
| Post Market Time | 1,787,960,636 |
| Previous Close | 3.82 |
| Price Eps Current Year | -18.96277 |
| Price Hint | 4 |
| Price To Book | 6.3712373 |
| Price To Sales Trailing12 Months | 2.1816537 |
| Profit Margins | -0.12354 |
| Quick Ratio | 2.891 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.09091 |
| Region | US |
| Regular Market Change | -0.00999999 |
| Regular Market Change Percent | -0.26178 |
| Regular Market Day High | 3.8995 |
| Regular Market Day Low | 3.75 |
| Regular Market Day Range | 3.75 - 3.8995 |
| Regular Market Open | 3.81 |
| Regular Market Previous Close | 3.82 |
| Regular Market Price | 3.81 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 5,133,259 |
| Return On Assets | -0.0425 |
| Return On Equity | -0.38609 |
| Revenue Growth | 0.238 |
| Revenue Per Share | 1.841 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 258,187,572 |
| Shares Percent Shares Out | 0.086899996 |
| Shares Short | 22,433,157 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 26,248,733 |
| Short Name | Ardelyx, Inc. |
| Short Percent Of Float | 0.0887 |
| Short Ratio | 5.23 |
| Source Interval | 15 |
| State | MA |
| Symbol | ARDX |
| Target High Price | 18.0 |
| Target Low Price | 8.0 |
| Target Mean Price | 12.9 |
| Target Median Price | 13.5 |
| Total Cash | 281,830,016 |
| Total Cash Per Share | 1.131 |
| Total Debt | 282,507,008 |
| Total Revenue | 450,894,016 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.23 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 5.918475 |
| Two Hundred Day Average Change | -2.1084752 |
| Two Hundred Day Average Change Percent | -0.35625312 |
| Type Disp | Equity |
| Volume | 5,133,259 |
| Website | https://www.ardelyx.com |
| Zip | 2,451 |